BioNTech SE - American Depositary Shares (NQ:BNTX)

92.50 +1.04 (+1.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

71 72 Next >

What's Going With BioNTech Stock On Monday? ↗

May 06, 2024

BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves.

Via Benzinga

BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit ↗

May 06, 2024

BioNTech missed the Street's sales views and reported wider-than-expected losses.

Via Investor's Business Daily

BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

May 06, 2024

Via Benzinga

Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young' ↗

May 06, 2024

U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to support the market, with S&P 500 earnings expected to grow by 5%...

Via Benzinga

Topics Economy

Assessing BioNTech: Insights From 11 Financial Analysts ↗

April 17, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For BioNTech ↗

March 21, 2024

Via Benzinga

BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

May 06, 2024

From BioNTech SE

Via GlobeNewswire

GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook ↗

May 01, 2024

Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix....

Via Benzinga

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle ↗

April 26, 2024

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...

Via Benzinga

Topics Intellectual Property Lawsuit

What's Going On With Pfizer Stock On Thursday? ↗

April 25, 2024

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.

Via Benzinga

Topics Intellectual Property

Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report ↗

May 06, 2024

According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.

Via Benzinga

Topics Stocks

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown ↗

April 23, 2024

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.

Via Benzinga

Topics Intellectual Property

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

April 22, 2024

From BioNTech SE

Via GlobeNewswire

Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert ↗

April 12, 2024

Via Benzinga

Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024? ↗

April 09, 2024

These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.

Via InvestorPlace

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

April 07, 2024

From BioNTech SE

Via GlobeNewswire

CureVac, GS Partner Release Data On Influenza Vaccine Study ↗

April 04, 2024

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...

Via Benzinga

The 3 Best Bargain Stocks to Buy in Q2 2024 ↗

March 31, 2024

For those who don’t want to chase what everyone else is acquiring, these are intriguing ideas for best bargain stocks to buy.

Via InvestorPlace

3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗

March 26, 2024

These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.

Via InvestorPlace

BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript ↗

March 20, 2024

BNTX earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 20, 2024

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and...

Via Benzinga

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials ↗

March 20, 2024

BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine.

Via Benzinga

Stocks Quietly Higher As Central Bank Wraps Up Meeting ↗

March 20, 2024

Stocks are cautiously higher ahead of the conclusion of the central bank's policy meeting.

Via Talk Markets

Topics Economy

BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q4 2023 ↗

March 20, 2024

BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts ↗

March 20, 2024

BioNTech also reported plummeting earnings that missed forecasts and issued light 2024 guidance.

Via Investor's Business Daily

Why Is BioNTech Stock Trading Lower On Wednesday? ↗

March 20, 2024

BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missing consensus. Guidance for 2024 anticipates revenues of €2.5-€3.1 billion,...

Via Benzinga

US Stock Futures Stall As Traders Await Fed Chair Powell's Decision; Analyst Sees S&P 500 Showing 'Signs Of Near-Term Top' ↗

March 20, 2024

Investors remain cautious ahead of the Federal Reserve‘s interest rate decision, with stock futures on Wednesday hinting at a lower opening.

Via Benzinga

Topics Economy Stocks

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

March 20, 2024

From BioNTech SE

Via GlobeNewswire

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

March 20, 2024

From BioNTech SE

Via GlobeNewswire

Earnings Scheduled For March 20, 2024 ↗

March 20, 2024

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.